Oriola-KD Oyj: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Oriola-KD expects net sales and operating profit to grow in FY 2014
Oriola-KD Oyj:Sees FY 2014 net sales and operating profit excluding non-recurring items to increase compared to 2013 actual.Reported net sales of 2,598.5 million euros and operating profit excluding non-recurring of 29.0 million euros in FY 2013.FY 2014 revenue 2,704 million euros, EBIT 42.89 million euros - Thomson Reuters I/B/E/S Estimates.
Latest Developments for Oriola-KD Oyj
- Oriola-KD issues FY 2015 guidance with net sales outlook in line with estimates
- Oriola-KD Oyj's nomination committee proposes Anssi Vanjoki as Chairman of Board of Directors
- Oriola-KD Oyj to begin co-operation negotiations in Finland
- Oriola-KD revises guidance for continuing operations net sales and operating profit excluding non-recurring items in FY 2014
Latest Key Developments in Drug
- WELCIA HOLDINGS updates to acquire companies through stock swap
- AmerisourceBergen completes acquisition of MWI Veterinary Supply Inc
- AmerisourceBergen Corp completes tender offer for outstanding shares of MWI Veterinary Supply, Inc
- Express Scripts gives FY 2015 earnings guidance in line with analysts' estimates
- Share this
- Digg this